A Phase I, randomized, double-blind crossover study of CAL-101, an oral inhibitor of phosphatidylinositol 3-kinase (PI3K) delta, in patients with allergic rhinitis.
The purpose of this study is to determine the safety and effect of CAL-101 in subjects with allergic rhinitis.